<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="940">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391920</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001</org_study_id>
    <secondary_id>FDA EUA</secondary_id>
    <nct_id>NCT04391920</nct_id>
  </id_info>
  <brief_title>Registry of CytoSorb Therapy in COVID-19 ICU Patients</brief_title>
  <acronym>CTC REGISTRY</acronym>
  <official_title>Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY): Registry of Patient-level Clinical Data on CytoSorb Hemoadsorption Provided Via Integration of the CytoSorb Device Into Extracorporeal Membrane Oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), or Hemoperfusion Extracorporeal Circuits in COVID-19 ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoSorbents, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to
      COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or
      hemoperfusion extracorporeal circuits under the FDA Emergency Use Authorization for this
      CytoSorb device use. The intent of the registry is to gain understanding on how CytoSorb
      hemoadsorption provides clinical benefit to COVID-19 ICU patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>From the date of start of CytoSorb use until the date of ICU discharge or date of death, whichever comes first, assessed up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ECMO after start of CytoSorb</measure>
    <time_frame>From the date of start of CytoSorb use until the date of cessation of ECMO or date of death, which ever comes first, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilatory support after start of CytoSorb</measure>
    <time_frame>From the date of start of CytoSorb use until the date of cessation of mechanical ventilatory support or date of death, which ever comes first, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of pharmacologic hemodynamic support after start of CytoSorb</measure>
    <time_frame>From the date of start of CytoSorb use until the date of cessation of pharmacologic hemodynamic support or date of death, which ever comes first, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentrations of inflammatory biomarkers after start of CytoSorb</measure>
    <time_frame>From the day before start of CytoSorb use until the day after cessation of CytoSorb use</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>COVID-19 ICU Patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb 300 mL device</intervention_name>
    <description>CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.</description>
    <arm_group_label>COVID-19 ICU Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 ICU patients receiving CytoSorb hemoadsorption via integration of the CytoSorb
        device into ECMO, CRRT, or hemoperfusion extracorporeal circuits under the FDA Emergency
        Use Authorization for this CytoSorb device use.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed COVID-19

          2. ICU admission

          3. Confirmed or imminent respiratory failure

          4. CytoSorb hemoadsorption via integration of the CytoSorb device into ECMO, CRRT, or
             hemoperfusion extracorporeal circuits.

        Exclusion Criteria:

          1. Platelet counts &lt; 20,000/μL

          2. Any pre-existing contraindication to extracorporeal therapy

          3. Known allergies to extracorporeal circuit components

          4. History of heparin-induced thrombocytopenia

          5. Acute sickle cell crisis

          6. Morbid obesity with BMI ≥ 40 kg/m2

          7. Any pre-existing advanced medical disease with life-expectancy less than 1 month

          8. CytoSorb hemoadsorption deemed clinically futile

          9. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Nelson, MD</last_name>
    <role>Study Director</role>
    <affiliation>CytoSorbents Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenni Stokes, RN</last_name>
    <phone>(704) 578-2425</phone>
    <email>jstokes@cytosorbents.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Center of Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenni Stokes, RN</last_name>
      <email>jstokes@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenni Stokes, RN</last_name>
      <email>jstokes@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Southaven</city>
        <state>Mississippi</state>
        <zip>38671</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenni Stokes, RN</last_name>
      <email>jstokes@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenni Stokes, RN</last_name>
      <email>jstokes@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenni Stokes, RN</last_name>
      <email>jstokes@cytosorbents.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

